{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:24:26Z","timestamp":1791944666296,"version":"4.3.4"},"reference-count":75,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,4,9]],"date-time":"2023-04-09T00:00:00Z","timestamp":1680998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCDD"],"abstract":"<jats:p>Dual antiplatelet therapy (DAPT), consisting of the combination of aspirin and an inhibitor of the platelet P2Y12 receptor for ADP, remains among the most investigated treatments in cardiovascular medicine. While a substantial amount of research initially stemmed from the observations of late and very late stent thrombosis events in the first-generation drug-eluting stent (DES) era, DAPT has been recently transitioning from a purely stent-related to a more systemic secondary prevention strategy. Oral and parenteral platelet P2Y12 inhibitors are currently available for clinical use. The latter have been shown to be extremely suitable in drug-na\u00efve patients with acute coronary syndrome (ACS), mainly because oral P2Y12 inhibitors are associated with delayed efficacy in patients with STEMI and because pre-treatment with P2Y12 inhibitors is discouraged in NSTE-ACS, and in patients with recent DES implantation and in need of urgent cardiac and non-cardiac surgery. More definitive evidence is needed, however, about optimal switching strategies between parenteral and oral P2Y12 inhibitors and about newer potent subcutaneous agents that are being developed for the pre-hospital setting.<\/jats:p>","DOI":"10.3390\/jcdd10040163","type":"journal-article","created":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T03:15:57Z","timestamp":1681096557000},"page":"163","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Dual Antiplatelet Therapy with Parenteral P2Y12 Inhibitors: Rationale, Evidence, and Future Directions"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0615-0811","authenticated-orcid":false,"given":"Giulia","family":"Alagna","sequence":"first","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, 98124 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Mazzone","sequence":"additional","affiliation":[{"name":"Cardiology Unit, \u201cUmberto I\u201d Hospital, 96100 Siracusa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Contarini","sequence":"additional","affiliation":[{"name":"Cardiology Unit, \u201cUmberto I\u201d Hospital, 96100 Siracusa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5552-6382","authenticated-orcid":false,"given":"Giuseppe","family":"And\u00f2","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, 98124 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,4,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1056\/NEJM199812033392303","article-title":"A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators","volume":"339","author":"Leon","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1056\/NEJM199604253341702","article-title":"A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents","volume":"334","author":"Neumann","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(04)17275-9","article-title":"Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy","volume":"364","author":"McFadden","year":"2004","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1016\/j.jacc.2015.03.003","article-title":"Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction","volume":"65","author":"Yeh","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/j.jcin.2022.08.009","article-title":"P2Y(12) Inhibitor or Aspirin Following Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Network Meta-Analysis","volume":"15","author":"Ando","year":"2022","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.120.052008","article-title":"Coronary Optical Coherence Tomography and Cardiac Magnetic Resonance Imaging to Determine Underlying Causes of Myocardial Infarction With Nonobstructive Coronary Arteries in Women","volume":"143","author":"Reynolds","year":"2021","journal-title":"Circulation"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41569-019-0273-3","article-title":"Non-atherosclerotic causes of acute coronary syndromes","volume":"17","author":"Waterbury","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3109\/17482941003732758","article-title":"Transient left ventricular dysfunction in patients with neurovascular events","volume":"12","author":"Ando","year":"2010","journal-title":"Acute Card Care"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1016\/j.jacc.2020.08.053","article-title":"Timing of Oral P2Y(12) Inhibitor Administration in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome","volume":"76","author":"Tarantini","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/ncpcardio0602","article-title":"Drug insight: Clopidogrel nonresponsiveness","volume":"3","author":"Gurbel","year":"2006","journal-title":"Nat. Clin. Pract. Cardiovasc. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40262-014-0230-6","article-title":"Clinical pharmacokinetics and pharmacodynamics of clopidogrel","volume":"54","author":"Jiang","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"66.e9","DOI":"10.1016\/j.ahj.2006.10.010","article-title":"A comparison of prasugrel and clopidogrel loading doses on platelet function: Magnitude of platelet inhibition is related to active metabolite formation","volume":"153","author":"Brandt","year":"2007","journal-title":"Am. Heart J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1056\/NEJMoa1908973","article-title":"Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes","volume":"381","author":"Neumann","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"42","author":"Collet","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1160\/TH12-08-0547","article-title":"Why does ticagrelor induce dyspnea?","volume":"108","author":"Cattaneo","year":"2012","journal-title":"Thromb. Haemost."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1161\/CIRCINTERVENTIONS.112.972323","article-title":"Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction","volume":"5","author":"Alexopoulos","year":"2012","journal-title":"Circ. Cardiovasc. Interv."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jcin.2012.01.006","article-title":"Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: The FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial","volume":"5","author":"Valgimigli","year":"2012","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.jacc.2013.01.024","article-title":"Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study","volume":"61","author":"Parodi","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jacc.2014.08.056","article-title":"Ticagrelor crushed tablets administration in STEMI patients: The MOJITO study","volume":"65","author":"Parodi","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/j.jacc.2016.02.045","article-title":"Crushed Prasugrel Tablets in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention: The CRUSH Study","volume":"67","author":"Rollini","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.thromres.2016.10.013","article-title":"Chewed ticagrelor tablets provide faster platelet inhibition compared to integral tablets: The inhibition of platelet aggregation after administration of three different ticagrelor formulations (IPAAD-Tica) study, a randomised controlled trial","volume":"149","author":"Venetsanos","year":"2017","journal-title":"Thromb. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1161\/CIRCULATIONAHA.118.034790","article-title":"Study of Two Dose Regimens of Ticagrelor Compared with Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention for Stable Coronary Artery Disease (STEEL-PCI)","volume":"138","author":"Orme","year":"2018","journal-title":"Circulation"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1111\/jth.14434","article-title":"Efficacy and safety of alternative oral administrations of P2Y12-receptor inhibitors: Systematic review and meta-analysis","volume":"17","author":"Serenelli","year":"2019","journal-title":"J. Thromb. Haemost."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1080\/14779072.2021.1920925","article-title":"Tackling the gap in platelet inhibition with oral antiplatelet agents in high-risk patients undergoing percutaneous coronary intervention","volume":"19","author":"Capranzano","year":"2021","journal-title":"Expert. Rev. Cardiovasc. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/00024382-200115050-00001","article-title":"The mesenteric hemodynamic response to circulatory shock: An overview","volume":"15","author":"Reilly","year":"2001","journal-title":"Shock"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s12928-017-0475-8","article-title":"Platelet inhibition after loading dose of prasugrel in patients with ST-elevation and non-ST-elevation acute coronary syndrome","volume":"33","author":"Wakabayashi","year":"2018","journal-title":"Cardiovasc. Interv. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jacc.2021.05.015","article-title":"Orodispersible Ticagrelor in Acute Coronary Syndromes: The TASTER Study","volume":"78","author":"Parodi","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s40262-020-00864-4","article-title":"Pharmacokinetics and Pharmacodynamics of Approved and Investigational P2Y12 Receptor Antagonists","volume":"59","author":"Schilling","year":"2020","journal-title":"Clin. Pharmacokinet."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1056\/NEJMoa1300815","article-title":"Effect of platelet inhibition with cangrelor during PCI on ischemic events","volume":"368","author":"Bhatt","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Zwart, B., Parker, W.A.E., and Storey, R.F. (2020). New Antithrombotic Drugs in Acute Coronary Syndrome. J. Clin. Med., 9.","DOI":"10.3390\/jcm9072059"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1016\/j.bmcl.2014.06.070","article-title":"Optimization of 2-phenyl-pyrimidine-4-carboxamides towards potent, orally bioavailable and selective P2Y(12) antagonists for inhibition of platelet aggregation","volume":"24","author":"Caroff","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/09537104.2020.1714574","article-title":"Novel approaches to P2Y(12) inhibition and aspirin dosing","volume":"32","author":"Parker","year":"2021","journal-title":"Platelets"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e00338","DOI":"10.1002\/prp2.338","article-title":"The reversible P2Y(12) antagonist ACT-246475 causes significantly less blood loss than ticagrelor at equivalent antithrombotic efficacy in rat","volume":"5","author":"Rey","year":"2017","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1080\/00498254.2019.1646440","article-title":"Absorption, distribution, metabolism and excretion of the P2Y12 receptor antagonist selatogrel after subcutaneous administration in healthy subjects","volume":"50","author":"Ufer","year":"2020","journal-title":"Xenobiotica"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1093\/eurheartj\/ehz807","article-title":"Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes","volume":"41","author":"Storey","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1016\/j.jacc.2020.03.059","article-title":"Subcutaneous Selatogrel Inhibits Platelet Aggregation in Patients With Acute Myocardial Infarction","volume":"75","author":"Sinnaeve","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e362","DOI":"10.4244\/EIJV17I5A63","article-title":"Subcutaneous RUC-4 for acute myocardial infarction: A new treatment on the horizon for pre-hospital care?","volume":"17","author":"Valgimigli","year":"2021","journal-title":"EuroIntervention"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e016552","DOI":"10.1161\/JAHA.120.016552","article-title":"First Human Use of RUC-4: A Nonactivating Second-Generation Small-Molecule Platelet Glycoprotein IIb\/IIIa (Integrin alphaIIbbeta3) Inhibitor Designed for Subcutaneous Point-of-Care Treatment of ST-Segment-Elevation Myocardial Infarction","volume":"9","author":"Kereiakes","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e401","DOI":"10.4244\/EIJ-D-21-00287","article-title":"Pharmacokinetics, pharmacodynamics, and tolerability of subcutaneous administration of a novel glycoprotein IIb\/IIIa inhibitor, RUC-4, in patients with ST-segment elevation myocardial infarction","volume":"17","author":"Bor","year":"2021","journal-title":"EuroIntervention"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s11239-015-1233-3","article-title":"Impact of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: Insights from the CHAMPION trials","volume":"40","author":"Angiolillo","year":"2015","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1517\/14740338.2016.1133585","article-title":"A Safety Evaluation of Cangrelor in Patients Undergoing PCI","volume":"15","author":"Franchi","year":"2016","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/2048872617707960","article-title":"Practical considerations for cangrelor use in patients with acute coronary syndromes","volume":"8","author":"Leonardi","year":"2019","journal-title":"Eur. Heart J. Acute Cardiovasc. Care"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa0908629","article-title":"Intravenous platelet blockade with cangrelor during PCI","volume":"361","author":"Bhatt","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: A consensus report from the Bleeding Academic Research Consortium","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1056\/NEJMoa0908628","article-title":"Platelet inhibition with cangrelor in patients undergoing PCI","volume":"361","author":"Harrington","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2217\/fca-2019-0095","article-title":"Cangrelor in clinical use","volume":"16","author":"Feng","year":"2020","journal-title":"Future Cardiol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ahj.2011.11.001","article-title":"Reduced immediate ischemic events with cangrelor in PCI: A pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction","volume":"163","author":"White","year":"2012","journal-title":"Am. Heart J."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1016\/j.jcin.2016.06.046","article-title":"Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial","volume":"9","author":"Abtan","year":"2016","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/S0140-6736(13)61615-3","article-title":"Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: A pooled analysis of patient-level data","volume":"382","author":"Steg","year":"2013","journal-title":"Lancet"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1161\/CIRCULATIONAHA.118.038317","article-title":"Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention","volume":"139","author":"Franchi","year":"2019","journal-title":"Circulation"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1080\/09537104.2016.1246714","article-title":"Cangrelor in combination with ticagrelor provides consistent and potent P2Y12-inhibition during and after primary percutaneous coronary intervention in real-world patients with ST-segment-elevation myocardial infarction","volume":"28","author":"Mohammad","year":"2017","journal-title":"Platelets"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/j.jacc.2018.07.041","article-title":"Cangrelor in Ticagrelor-Loaded STEMI Patients Undergoing Primary Percutaneous Coronary Intervention","volume":"72","author":"Alexopoulos","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jcin.2022.10.034","article-title":"Cangrelor in Patients With Coronary Artery Disease Pretreated With Ticagrelor: The Switching Antiplatelet (SWAP)-5 Study","volume":"16","author":"Franchi","year":"2023","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/ehjcvp\/pvz002","article-title":"Clinical use of cangrelor: Nationwide experience from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)","volume":"5","author":"Lagerqvist","year":"2019","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nrcardio.2017.18","article-title":"Antithrombotic therapy for patients with STEMI undergoing primary PCI","volume":"14","author":"Franchi","year":"2017","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1016\/j.jcin.2019.05.028","article-title":"Effects of Methylnaltrexone on Ticagrelor-Induced Antiplatelet Effects in Coronary Artery Disease Patients Treated With Morphine","volume":"12","author":"Franchi","year":"2019","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e024513","DOI":"10.1161\/JAHA.121.024513","article-title":"Cangrelor Use Patterns and Transition to Oral P2Y(12) Inhibitors Among Patients With Myocardial Infarction: Initial Results From the CAMEO Registry","volume":"11","author":"Rymer","year":"2022","journal-title":"J. Am. Heart Assoc."},{"key":"ref_63","first-page":"1269","article-title":"Cangrelor for comatose survivors of out-of-hospital cardiac arrest undergoing percutaneous coronary intervention: The CANGRELOR-OHCA study","volume":"18","author":"Kordis","year":"2023","journal-title":"EuroIntervention"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/clc.23878","article-title":"Use of cangrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention: Study design and interim analysis of the ARCANGELO study","volume":"45","author":"Chirillo","year":"2022","journal-title":"Clin. Cardiol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jcin.2016.10.004","article-title":"Randomized Comparison of Oral P2Y(12)-Receptor Inhibitor Loading Strategies for Transitioning From Cangrelor: The ExcelsiorLOAD2 Trial","volume":"10","author":"Hochholzer","year":"2017","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jcin.2016.11.021","article-title":"Drug-Drug Interactions When Switching Between Intravenous and Oral P2Y(12) Receptor Inhibitors: How Real Is It?","volume":"10","author":"Rollini","year":"2017","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1161\/CIRCULATIONAHA.120.046928","article-title":"Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS-FASTER Trial","volume":"142","author":"Gargiulo","year":"2020","journal-title":"Circulation"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11239-012-0737-3","article-title":"Pharmacodynamic effects of cangrelor and clopidogrel: The platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials","volume":"34","author":"Angiolillo","year":"2012","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/MCA.0000000000000158","article-title":"Pharmacodynamic effects during the transition between cangrelor and prasugrel","volume":"26","author":"Schneider","year":"2015","journal-title":"Coron Artery Dis."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jcin.2013.08.017","article-title":"Pharmacodynamic effects during the transition between cangrelor and ticagrelor","volume":"7","author":"Schneider","year":"2014","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_71","first-page":"1266","article-title":"Pharmacodynamic effects of cangrelor in elective complex PCI: Insights from the POMPEII Registry","volume":"18","author":"Gargiulo","year":"2023","journal-title":"EuroIntervention"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1001\/jama.2011.2002","article-title":"Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: A randomized controlled trial","volume":"307","author":"Angiolillo","year":"2012","journal-title":"JAMA"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jcin.2017.10.051","article-title":"A Multidisciplinary Approach on the Perioperative Antithrombotic Management of Patients With Coronary Stents Undergoing Surgery: Surgery After Stenting 2","volume":"11","author":"Rossini","year":"2018","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e437","DOI":"10.1055\/s-0040-1721504","article-title":"Antiplatelet Therapy with Cangrelor in Patients Undergoing Surgery after Coronary Stent Implantation: A Real-World Bridging Protocol Experience","volume":"4","author":"Rossini","year":"2020","journal-title":"TH Open"}],"container-title":["Journal of Cardiovascular Development and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2308-3425\/10\/4\/163\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:12:43Z","timestamp":1760123563000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2308-3425\/10\/4\/163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,9]]},"references-count":75,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["jcdd10040163"],"URL":"https:\/\/doi.org\/10.3390\/jcdd10040163","relation":{},"ISSN":["2308-3425"],"issn-type":[{"value":"2308-3425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,9]]}}}